{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:44:42Z","timestamp":1764603882708,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The usage of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gynecological cancers is increasing. Methods: Prospectively collected data of 85 advanced primary ovarian\/fallopian tube cancer and peritoneal carcinoma patients of a single center were investigated. Results: A total 48, 37, 62, and 25 patients were enrolled into the HIPEC with\/without neoadjuvant chemotherapy (upfront vs. interval) and into the 60 min and 90 min long HIPEC groups, respectively. Better overall survival (OS) was observed in the 90 min HIPEC group (p = 0.0330), compared to the 60 min HIPEC group. Neither OS (p = 0. 2410), disease-specific (p = 0. 3670), nor recurrence-free survival (p = 0.8240) differed between upfront and interval HIPEC. Higher peritoneal carcinomatosis index (PCI) values were associated with worse disease-specific survival (p = 0.0724). Age (p = 0.0416), body mass index (p = 0.0044), PCI (p &lt; 0.0001), the type (p = 0.0016) and duration (p = 0.0012) of HIPEC, and increased perioperative morbidity (p &lt; 0.0041) had the greatest impact on OS. Conclusions: Increasing data support the value of HIPEC in the treatment of advanced ovarian cancer. Ongoing prospective studies will definitively clarify the role and timing of this additional therapeutic approach.<\/jats:p>","DOI":"10.3390\/cancers14143301","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T09:41:10Z","timestamp":1657100470000},"page":"3301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-5541","authenticated-orcid":false,"given":"Miklos","family":"Acs","sequence":"first","affiliation":[{"name":"Department of General and Visceral Surgery, Hospital Barmherzige Br\u00fcder, 93049 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-4889","authenticated-orcid":false,"given":"Zoltan","family":"Herold","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila Marcell","family":"Szasz","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Mayr","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Hospital Barmherzige Br\u00fcder, 93049 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"H\u00e4usler","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Gynecological Oncology, Hospital Barmherzige Br\u00fcder, 93049 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompiliu","family":"Piso","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Hospital Barmherzige Br\u00fcder, 93049 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","article-title":"An international assessment of ovarian cancer incidence and mortality","volume":"130","author":"Lowe","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.21037\/jgo-2020-06","article-title":"Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience","volume":"12","author":"Coccolini","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.21873\/anticanres.14092","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort","volume":"40","author":"Friedrich","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Riggs, M.J., Pandalai, P.K., Kim, J., and Dietrich, C.S. (2020). Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010043"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jso.26280","article-title":"Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: Results of a retrospective study","volume":"123","author":"Spiliotis","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/02656736.2018.1518544","article-title":"Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"35","author":"Decullier","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jogoh.2019.03.018","article-title":"Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: Systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)","volume":"48","author":"Lavoue","year":"2019","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer","volume":"32","author":"Tokunaga","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12094-020-02545-x","article-title":"SEOM clinical guideline in ovarian cancer (2020)","volume":"23","author":"Redondo","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_14","unstructured":"Deutsche Krebsgesellschaft, D.K. AWMF. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Langversion 4.0, AWMF Registrierungsnummer: 032\/035OL 2020."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Naticchioni","year":"2008","journal-title":"Cancer"},{"key":"ref_16","first-page":"224","article-title":"Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center","volume":"42","author":"Rubio","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomised trial of hyperthermic intraperitneal chemotherapy (HIPEC) in women with advanced peritoneal, ovarian and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","article-title":"2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer","volume":"133","author":"Mutch","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_20","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet","year":"1996","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_22","first-page":"65","article-title":"A Simple Sequentially Rejective Multiple Test Procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand. J. Stat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2016.07.014","article-title":"Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO","volume":"66","author":"Klar","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","article-title":"Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon","volume":"100","author":"Aletti","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","article-title":"Intraperitoneal chemotherapy in the management of malignant disease","volume":"1","author":"Markman","year":"2001","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_32","first-page":"56","article-title":"Dose enhancement effect of anticaner drugs associated with increased temperature in vitro","volume":"30","author":"Istomin","year":"2008","journal-title":"Exp. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01212608","article-title":"Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells","volume":"123","author":"Rietbroek","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Helderman, R., Loke, D.R., Kok, H.P., Oei, A.L., Tanis, P.J., Franken, N., and Crezee, J. (2019). Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers, 11.","DOI":"10.3390\/cancers11010078"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejso.2018.10.528","article-title":"Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis","volume":"45","author":"Wang","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.21873\/anticanres.15563","article-title":"Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Doxorubicin for 90 Minutes Versus 60 Minutes after Cytoreductive Surgery (CRS). Does the 30-Minute Difference Matter? A Comparative Study in a High Volume Centre","volume":"42","author":"Acs","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2013.11.035","article-title":"Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study","volume":"132","author":"Ottesen","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/EDBK_160624","article-title":"Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues","volume":"35","author":"Leary","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101523","DOI":"10.1016\/j.suronc.2021.101523","article-title":"A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer","volume":"37","author":"Marrelli","year":"2021","journal-title":"Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/ijgc-2020-002081","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: The tail of the scorpion for radical debulking surgery?","volume":"30","author":"Fotopoulou","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3802\/jgo.2020.31.e34","article-title":"Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and primary peritoneal cancer","volume":"31","author":"Tate","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Carboni, F., Federici, O., Sperduti, I., Zazza, S., Sergi, D., Corona, F., and Valle, M. (2021). Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience. Cancers, 13.","DOI":"10.3390\/cancers13030523"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","article-title":"A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy","volume":"154","author":"Bartels","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_50","first-page":"27","article-title":"Lighting the Way for Improved Detection of Ovarian Cancer","volume":"327","author":"Voelker","year":"2022","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3802\/jgo.2020.31.e17","article-title":"Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery","volume":"31","author":"Liu","year":"2020","journal-title":"J. Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:33Z","timestamp":1760139813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":52,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143301"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143301","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}